457 related articles for article (PubMed ID: 16613848)
1. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption.
Zheng H; Yu X; Collin-Osdoby P; Osdoby P
J Biol Chem; 2006 Jun; 281(23):15809-20. PubMed ID: 16613848
[TBL] [Abstract][Full Text] [Related]
2. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
Bharti AC; Takada Y; Aggarwal BB
J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
[TBL] [Abstract][Full Text] [Related]
3. Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling?
Van Bezooijen RL; Papapoulos SE; Löwik CW
Bone; 2001 Apr; 28(4):378-86. PubMed ID: 11336918
[TBL] [Abstract][Full Text] [Related]
4. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation.
Hayashi T; Kaneda T; Toyama Y; Kumegawa M; Hakeda Y
J Biol Chem; 2002 Aug; 277(31):27880-6. PubMed ID: 12023971
[TBL] [Abstract][Full Text] [Related]
5. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
Song J; Jing Z; Hu W; Yu J; Cui X
Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
[TBL] [Abstract][Full Text] [Related]
6. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Zhang Z; Jimi E; Bothwell AL
J Immunol; 2003 Oct; 171(7):3620-6. PubMed ID: 14500659
[TBL] [Abstract][Full Text] [Related]
7. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
8. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T
Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749
[TBL] [Abstract][Full Text] [Related]
9. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-kappaB-dependent, CD40-mediated bone destruction in rheumatoid arthritis.
Lee HY; Jeon HS; Song EK; Han MK; Park SI; Lee SI; Yun HJ; Kim JR; Kim JS; Lee YC; Kim SI; Kim HR; Choi JY; Kang I; Kim HY; Yoo WH
Arthritis Rheum; 2006 Jun; 54(6):1747-58. PubMed ID: 16736517
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
11. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
12. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
[TBL] [Abstract][Full Text] [Related]
13. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of inducible nitric-oxide synthase expression by (5R)-5-hydroxytriptolide in interferon-gamma- and bacterial lipopolysaccharide-stimulated macrophages.
Zhou R; Zheng SX; Tang W; He PL; Li XY; Yang YF; Li YC; Geng JG; Zuo JP
J Pharmacol Exp Ther; 2006 Jan; 316(1):121-8. PubMed ID: 16166270
[TBL] [Abstract][Full Text] [Related]
15. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
[TBL] [Abstract][Full Text] [Related]
16. IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling.
Mangashetti LS; Khapli SM; Wani MR
J Immunol; 2005 Jul; 175(2):917-25. PubMed ID: 16002690
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts.
Takuma A; Kaneda T; Sato T; Ninomiya S; Kumegawa M; Hakeda Y
J Biol Chem; 2003 Nov; 278(45):44667-74. PubMed ID: 12944401
[TBL] [Abstract][Full Text] [Related]
18. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
19. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
20. Soluble glucocorticoid-induced tumor necrosis factor receptor (sGITR) stimulates osteoclast differentiation in response to receptor activator of NF-kappaB ligand (RANKL) in osteoclast cells.
Shin HH; Kim SJ; Lee DS; Choi HS
Bone; 2005 May; 36(5):832-9. PubMed ID: 15814301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
